Financial summary for the third quarter* July to September 2014 (2013) · Net turnover totalled SEK 617.8 million (SEK 80.2 m), SEK 516.4 million (SEK 0 m) of which comprised royalties for simeprevir. · Revenues from Medivir’s own pharmaceutical sales totalled SEK 100.8 million (SEK 36.6 m), SEK 61.6 million (SEK 0 m) of which derived from sales of Olysio® and SEK 39.2 million (SEK 36.6 m) from sales of other pharmaceuticals. · The profit/loss after tax was SEK 373.7 million (SEK -11.0 m). · Basic earnings per share totalled SEK 11.95 (SEK -0.35). · Diluted earnings per share totalled SEK 11.83 (SEK -0.35). · The cash flow from operating activities amounted to SEK 473.0 million (SEK -5.2 m). January to September 2014 (2013) · Net turnover totalled SEK 1,390.0 million (SEK 299.0 m), SEK 1,178.7 million (SEK 0 m) of which comprised royalties for simeprevir. · Revenues from Medivir’s own pharmaceutical sales totalled SEK 210.2 million (SEK 128.5 m), SEK 83.3 million (SEK 0 m) of which derived from sales of Olysio® and SEK 126.9 million (SEK 128.5 m) from sales of other pharmaceuticals. · The profit/loss after tax was SEK 985.4 million (SEK -40.5 m). · Basic earnings per share totalled SEK 31.52 (SEK -1.30). · Diluted earnings per share totalled SEK 31.21 (SEK -1.30). · The cash flow from operating activities amounted to SEK 504.0 million (SEK -32.5 m). · Liquid assets and short-term investments at the period end totalled SEK 896.4 million (SEK 337.7 m). Significant operational events During Q3 2014 · Continued strong market uptake and sales for Olysio®. · The FDA granted a Priority Review of the supplemental New Drug Application (sNDA) for treatment with Olysio® in combination with sofosbuvir. · Medivir in-licensed an RS virus drug programme from Boehringer Ingelheim. · Niklas Prager was appointed President & CEO of Medivir, effective as of 1 September. After the end of Q3 · Medivir organised a Capital Markets Meeting on 16 October 2014, to provide updates on the company’s status and strategy, along with details of the upcoming voluntary share redemption programme for a total of ca. SEK 625 million. · Medivir presented data from the cathepsin S inhibitor programme, including MIV-247, for the treatment of neuropathic pain at the 15th World Congress on Pain. · The launch of the phase II study, IMPACT, for the evaluation of simeprevir in combination with sofosbuvir and daclatasvir was announced. · Medivir entered into an agreement with Swedish county councils regarding risk sharing in connection with the treatment of hepatitis C using Olysio®. The agreement offers the county councils and Medivir an increased degree of predictability with regard to treatment costs and the use of Olysio®. · The U.S. Food and Drug Administration (FDA) has approved Olysio® (simeprevir) in combination with sofosbuvir as an all-oral, interferon- and ribavirin-free treatment option after review of the supplemental New Drug Application (sNDA). · Medivir convened an Extraordinary General Meeting for 20 November 2014 at 10.00 (CET) in Stockholm. · Medivir’s Nomination Committee for the 2015 Annual General Meeting has been appointed. * All figures refer to the Group, unless otherwise stated. Comparisons in the Interim Report are, unless otherwise stated, with the corresponding period in 2013. Cross Pharma was divested from the Group on 30 June 2013. The CEO’s statement Positive quarter with the emphasis on building value across the company I took over as President & CEO of Medivir on 1 September and it is very stimulating to take up this role in a company that is going through such an exciting developmental phase. The third quarter has seen us focusing strongly on the ongoing launch of our two new specialist pharmaceuticals, Olysio and Adasuve, in the Nordic market. Our research portfolio has also strengthened during the quarter with the in-licensing of an RSVdrug programme from Boehringer Ingelheim. This in-licensing further strengthens our position in the infectious disease area. We are also delighted by the growing revenue streams during the quarter being generated both by our own pharmaceutical sales and by the royalties we receive, even though Olysio can be expected to encounter increasingly tough competition in the international hepatitis C market. The market launch of Olysio (simeprevir) has been a success and the positive responses to Olysio received are clear confirmation of Medivir’s successful research and its innovative technology platform for the development of protease inhibitors. The successful launch is also proof of the extraordinary innovativeness within our organisation and of our ability to progress development in collaboration with our partners, all the way from preclinical research to a finished pharmaceutical product. The fact that we have successfully launched two new products in the Nordic market during the year - Olysio and Adasuve - shows that Medivir has a strong market organisation with the ability to launch innovative products in complex markets with varying regulatory requirements and differentiated health care systems. In October, we presented an update on the company’s strategy. Medivir will continue to be a Nordic, research-based company that exploits our market-leading expertise in the design of protease inhibitors and nucleotide/nucleoside research, with an emphasis on infectious diseases and oncology. We will also continue to build on our commercial operations through the in-licensing of specialist pharmaceuticals for the Nordic market. We have decided together with the Board of Directors and in the wake of a review of the company’s capital structure that the scope exists both for investments in the updated strategy and for a transfer of capital to our shareholders. The transfer will take place in two phases: the first is a voluntary share redemption programme for a total of SEK 625 million (SEK 20/share) after an Extraordinary General Meeting held on 20 November, while the second will be a request for a mandate to buy back shares that will be submitted at the Annual General Meeting in May 2015. The capital structure will be reviewed on a rolling basis. The third quarter saw a number of positive and important events in the hepatitis C area. The U.S. Food and Drug Administration (FDA) granted a Priority Review of the supplemental New Drug Application (sNDA) that refers to combination treatment with simeprevir and sofosbuvir. In November, the FDA announced that they had approved this interferon- and ribavirin-free combination treatment. The FDA’s Priority Review demonstrates the importance of interferon-free treatment alternatives for the large group of difficult-to-cure patients with hepatitis C. Our partner, Janssen, continues to demonstrate their intense commitment to continuing the development of new and improved treatment options for patients with hepatitis C, as was clearly demonstrated in the phase II IMPACT study announced in October. This is the first phase II study to investigate a combination of simeprevir, sofosbuvir and daclatasvir. We have also taken a number of important developmental steps forward with regard to our cathepsin inhibitor projects. Preclinical data from the cathepsin S inhibitor project were recently presented at a major scientific conference. The data suggest that MIV-247, which is our chosen candidate drug for continued development for the treatment of neuropathic pain, has the potential for use both as a first line use drug in conjunction with monotherapy and as an add-on to current treatments. Preparations are underway, as part of our osteoarthritis project, for the launch of a clinical phase IIa proof of concept study with MIV -711. The launch of any such study requires an expanded preclinical safety programme, and one such has recently been initiated. If everything goes well with this programme, a phase IIa study can be started in late 2015. We can now put an eventful and intensive quarter to rest and look to the future – a future which, in the short term, will entail a strong focus on implementing our strategy and continuing to build value across the company. Niklas Prager President & CEO For further information, please contact: Rein Piir, EVP Corporate Affairs & IR, +46 (0) 708 537292 Niklas Prager, President & CEO, +46 (0) 8 407 64 30 Conference call for investors, analysts and the media The Interim Report for the third quarter of 2014 will be presented by Medivir’s President & CEO, Niklas Prager, and members of the management group. Time: Thursday, 20 November 2014 at 14.00 (CET). Phone numbers for participants from: Sweden +46 (0)8 519 990 30 Europe +44 (0)20 766 020 77 USA +1 877 788 9023 The conference call will also be streamed via a link on the website: www.medivir.com. Financial calendar: Extraordinary General Meeting: 20 November 2014. The Financial Statement for January-December will be published on 27 February 2015. The Annual General Meeting will be held on 5 May 2015.
Interim Report, January – September 2014 Financial
Top 10 Most Recent News Articles
MERSCO’s Holiday Push Tests Backyard Play Demand in 2026
A trampoline sale is not exactly a macroeconomic bellwether, but it does expose a useful little corner of holiday spending: parents buying big, awkward, discretionary stuff that has to earn its space in the yard. MERSCO is joining Amazon’s Black Friday and Cyber Monday window from November 19 through November 30, 2026, with discounts reaching 38% on selected products....
Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum
Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...
Continue Reading
America's Group Adds Swansea to Its UK Auction Map
A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...
Continue Reading
Volta M100 Puts Flexibility at Pad Printing's Center
A tabletop printer rarely earns a second glance, but the Volta M100 is making a sensible argument: small manufacturers do not need another rigid box that becomes obsolete the minute a job changes. Boston Industrial Solutions has introduced the Volta M100 as a pad-printing machine built around adjustability, operator convenience, and software that can be upgraded as...
Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies
Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...
Continue Reading
Workday GO for Financials Targets the Messy Middle
Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...
Continue Reading
RazorMetrics' Fast 500 Run Merits a Harder Investor Look
A 4,488% growth figure can make even a seasoned skeptic sit upright. RazorMetrics landed at No. 20 on Deloitte's 2026 Technology Fast 500 after ranking No. 12 in 2025, and it again took the top Texas slot. That is serious momentum for an Austin company working on one of healthcare's most stubborn expenses: prescription drugs. Still, this is healthcare cost containment,...
Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test
Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...
Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem
Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...
Continue Reading
Three Deal Reviews Put Merger Terms Under Scrutiny
Three proposed transactions just picked up the sort of legal glare boards hate seeing. A shareholder-rights firm, Halper Sadeh, said on November 18, 2026 that it is investigating whether the deals involving Greenland Energy, Rapid Micro Biosystems and Aytu BioPharma may involve federal securities-law violations or breaches of fiduciary duty. That is an allegation worth...
Continue ReadingTop 5 Most Recently Viewed Articles
Ford Motor Company Faces Legal Challenges: Key Insights
Understanding the Legal Landscape for Ford Motor Company As investors navigate the intricate world of stock ownership, recent events surrounding Ford Motor Company have raised eyebrows. The company currently finds itself at the center of a class action lawsuit involving shareholders who acquired stock during a specific period. Class Action Overview and Important Dates...
Continue Reading
Transforming the Specialty Fats and Oils Industry for Success
A Deep Dive into the Specialty Fats and Oils Market The landscape of the specialty fats and oils market is rapidly transforming, growing from its valuation of US$ 16.12 billion in the preceding year to a staggering US$ 31.69 billion by 2033, marking a robust CAGR of 7.8% during the next financial stretch. This growth signals a significant shift in industry dynamics and...
Continue Reading
C3.ai: Analyzing Current Trends in the Options Market
Current Sentiment on C3.ai Recently, well-known investors—often referred to as whales—have taken a decidedly negative stance towards C3.ai. This growing skepticism stems from the history of options involving the company's stock. An analysis of C3.ai's (AI) trading patterns uncovered nine notable trades. Digging deeper into these transactions shows that only 22% of...
Continue Reading
CytomX Therapeutics Completes $100 Million Stock Offering
CytomX Therapeutics Completes $100 Million Stock Offering CytomX Therapeutics, Inc. (NASDAQ: CTMX), based in South San Francisco, has just announced the pricing of an extensive stock offering. The company is set to offer 76,923,076 shares of its common stock at a price of $1.30 per share. This significant transaction aims to raise approximately $100 million and is being...
Continue Reading
Wall Street's Bullish Coverage Initiation Highlights for NKE and Others
Wall Street Analysts Initiate Coverage on Key Stocks In a dynamic market landscape, top analysts have recently adjusted their ratings on several prominent companies. Their insights provide a glimpse into potential future performance for investors. Today, we spotlight these analyst ratings and what they mean for some notable stocks. NIKE, Inc. (NKE) Coverage by Needham...
Continue Reading